Welcome to the FTI-Project iLCA: Intelligent Live Cell Analysis [iLCA] to transform disease management through faster, and more regulatory robust, discovery, manufacture and monitoring of biologic drugs and cell therapies.
Our objective is to introduce an intelligent Live Cell Analysis platform into Cell Line Development [CLD] which provides end-users with a Manufacturability index containing detailed information on their clones, which is currently only available much later in the decision making process. The overarching objective of iLCA is to, over the next 24 months, rapidly validate the technical and economic performance of our disruptive process analytical platform at leading biopharmaceutical manufacturing sites.
ValitaCell Ltd develops novel high-throughput assay technologies to accelerate the manufacture of life-saving medicines. ValitaCell is headquartered in world-class facilities at NIBRT, Dublin with manufacturing capacity in Bernried, Munch, Germany. The company has won numerous industry awards, secured over €8million in funding and is actively selling to blue-chip clients internationally.
Solentim Ltd is a Life Sciences company, founded in 2010, specialising in Cell Line Development for the discovery and production of Bio-Pharmaceuticals market sector. The company is based outside Bournemouth, UK and sells internationally including to many of the world’s largest pharmaceutical companies.
Microcoat Biotechnologie GmbH was founded in 1992 as a spin-off of Boehringer Mannheim GmbH, at that time specialising in the coating of microplates. Microcoat is a privately held biotechnology company focused on development, production and application of diagnostic products and methods.
As we continue to develop the next generation of cell characterisation tools it is essential to consider their optimal integration into a variety of diverse manufacturing systems. Valitacell is working in collaboration with live cell imaging and automation partners in the CLD space to develop an integrated platform with transformative capabilities for the imaging and biomarker analysis of living cells. At the same time, we are extending the use of our platform technologies into the field of cell therapy and stem cell manufacturing. Through the European Union's Horizon 2020 INNOSUP programme, Valitacell have recruited Eligio F Iannetti, an Innovation Associate [II-LCA] to support the development of integrated imaging & analytic solutions for the CLD space, as well as define Valitacell’s technological and innovation needs for the development of technologies to support the stem cell manufacturing industry.
THESE PROJECTS HAVE RECEIVED FUNDING FROM THE EUROPEAN UNION’S HORIZON 2020 PROGRAMME0
ILCA – HORIZON 2020 [EIC-FTI] RESEARCH AND INNOVATION PROGRAM UNDER GRANT AGREEMENT NO 853886
II-LCA – HORIZON 2020 [INNOSUP] EUROPEAN SME INNOVATION ASSOCIATE – PILOT UNDER GRANT AGREEMENT NO 861845